Moreover, in contrast to previous reports13, the frequency of total TCM and of CD4+ TCM significantly decreased in relapsed F-MS patients compared to relapse-free F-MS patients (Fig. 2b). This evidence concerns the gene CD4 and myeloid sarcoma.